（文章来源：每日经济新闻） 每经AI快讯，有投资者在投资者互动平台提问：雅本公司已经与恒瑞签订战略合作，是否意味着雅本 与富美实的订单不会再续签？ 雅本化学（300261.SZ）8月6日在投资者互动平台表示，公司与恒瑞签订战略合作，核心目标为增强创 新医药 CDMO业务竞争力及扩大业务规模，与公司同富美实续签农药中间体订单事宜并无关联，且互 不影响。此外，尽管公司目前尚未与富美实完成协议续签，但双方相关业务合作仍在正常开展并共同积 极推动续签事宜，同时，公司仍在持续向其供货中。 ...

Group 1 - Yabonn Chemical has signed a strategic cooperation agreement with Heng Rui Medicine, establishing a partnership to enhance their competitive edge in the innovative pharmaceutical sector [1] - Heng Rui Medicine is recognized as a leading enterprise in China's innovative drug field, with significant achievements in drug research and development for major diseases [1] - Yabonn Chemical focuses on innovative pharmaceuticals and agricultural CDMO, implementing a major client strategy to optimize its pharmaceutical client structure and promote healthy business development [1] Group 2 - The company has decided to terminate the planned acquisition of a stake in Haotian Technology, citing strategic focus and resource allocation considerations [2] - The termination is influenced by the successful advancement of strategic cooperation with major clients like Heng Rui Medicine, leading to a preference for funding new product lines and R&D projects [2] - Yabonn Chemical aims to enhance its competitive position in the innovative pharmaceutical CDMO business by deepening external resource collaboration and optimizing resource allocation [2]